Nurse Practitioner Program year 2025 Source: CMS Open Payments, 2026 publication

Aaron Drapeau

Nurse Practitioner Kailua Kona, HI Nurse Practitioner

NPI 1780152959 CMS profile 11040999

75-5751 Kuakini Hwy Ste 101A, Kailua Kona, HI 96740

Open in the dashboard

General payments

$256

12 records reported · program year 2025

Research payments

$0

Paid to them · None reported · program year 2025

Ownership & investment interest

$0

None reported

Through program year 2025, Aaron Drapeau of Kailua Kona, HI is reported in the CMS Open Payments database as having received $256 across 12 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 44th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2025 General $256 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Aaron Drapeau
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Aaron Drapeau were reported at $256. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Aaron Drapeau Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $0 $152 $48–$470 $149
2023 $0 $166 $54–$529 $160
2024 $0 $173 $55–$556 $164
2025 $256 $174 $55–$557 $169

Breakdown

Who paid General payments · program year 2025
  1. GlaxoSmithKline, LLC. $43 2 payments
  2. Novo Nordisk Inc $39 2 payments
  3. Pfizer Inc. $28 1 payment
  4. Boston Scientific Corporation $27 1 payment
  5. AbbVie, Inc. $25 1 payment
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $22 1 payment
  7. Amgen Inc. $20 1 payment
  8. Dexcom, Inc. $19 1 payment
  9. Merck Sharp & Dohme Corporation $19 1 payment
  10. Verona Pharma, Inc. $14 1 payment

Every payment, record by record

What the payments were for General payments · program year 2025
  1. Food and Beverage $256 12 payments
Products named General payments · program year 2025
  1. NUCALA $43 2 payments
  2. NURTEC ODT $28 1 payment
  3. ZAVZPRET $28 1 payment
  4. WATCHMAN FLX $27 1 payment
  5. UBRELVY $25 1 payment
  6. QULIPTA $25 1 payment
  7. XIFAXAN $22 1 payment
  8. EVENITY $20 1 payment
  9. Dexcom G6 Transmitter $19 1 payment
  10. WINREVAIR $19 1 payment
  11. Other $14 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 39 drugs

Part D claims

1,181

Median for Nurse Practitioner: 389

Drug cost

$18,459

Median for Nurse Practitioner: $21,885

Branded share of claims

13.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 11 $5,005
Shingrix Varicella-Zoster Ge/As01b/Pf Brand 13 $2,868
Adacel Tdap Diph,pertuss(Acell),tet Vac/Pf Brand 17 $1,159
Losartan Potassium Generic 77 $931
Levothyroxine Sodium Generic 81 $672
Albuterol Sulfate Hfa Albuterol Sulfate Brand 20 $574
Metoprolol Succinate Generic 27 $568
Atorvastatin Calcium Generic 72 $530
Telmisartan Generic 13 $499
Gabapentin Generic 40 $490

The 10 drugs with the highest cost, of 39 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$33,344

Of which drugs: $2,537

Medicare patients

203

Average age 73

Services billed

792

122 women, 81 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 45%
Depression 24%
Cancer 23%
Ischemic heart disease 18%
Osteoporosis 18%
Diabetes 15%
Chronic kidney disease 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 14 14 $1,064

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

12 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Hawaii

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record